BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Telikibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Telikibart\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07199257-1374@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20270515
DTEND;VALUE=DATE:20270516
SUMMARY:Telikibart: Phase 3 readout est. (NCT07199257)
DESCRIPTION:Telikibart\, phase 3.\nStudy: A Study of GR1802 Injection in Pa
 tients With Seasonal Allergic Rhinitis.\nEstimated primary completion: 15 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telikibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0719
 9257
URL:https://assetmemo.bio/drug/telikibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
